PK and PD Study of IDN-6556 in Subjects With Severe Renal Impairment and Matched Healthy Volunteers
Condition: Renal Impairment; Renal Insufficiency; Kidney Disease; Kidney Diseases
MeSH terms: Kidney Diseases; Renal Insufficiency
Intervention: IDN-6556
Phase: Phase 1
Study type: Interventional
Primary purpose: Treatment
Allocation: Non-Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Enrollment: 16.0
Sex: All
Minimum age: 18 Years
Maximum age: 75 Years
Healthy volunteers: Accepts Healthy Volunteers
Keywords: pharmacokinetics; pharmacodynamics; renal impairment

Summary:

      This is an open-label, parallel-group study to compare the pharmacokinetics and
      pharmacodynamics of IDN-6556 following a single 50 mg oral dose of IDN-6556 in subjects with
      severe renal impairment and matched healthy volunteers with normal renal function.
    

Eligibility criteria:

        Inclusion Criteria:

        All Subjects:

          -  Male or female subjects 18 - 75 years of age, able to provide written informed
             consent, understand and comply with all scheduled visits, and other requirements of
             the study

          -  Body mass index (BMI) 18.0 - 40.0 kg/m2 and body weight >50 kg

          -  Willingness to utilize two reliable forms of contraception (for both males and females
             of childbearing potential) from screening to one month after the last dose of study
             drug

        Matched Healthy Volunteers:

          -  Medically healthy as determined by the Investigator

          -  Screening creatinine clearance ≥90 mL/min using the Cockcroft-Gault equation

          -  Supine blood pressure ≤145/90 mmHg

          -  No significant uncontrolled systemic or major illness that, in the opinion of the
             Investigator, would preclude the subject from participating in and completing the
             study

          -  Demographically comparable to subjects with severe renal impairment as follows:

               1. Mean body weight within ±10 kg

               2. Mean age within ±5 years

               3. Similar gender ratio

        Severe Renal Impaired Subjects:

          -  Screening creatinine clearance (CLCR) <30 mL/min using the Cockcroft-Gault equation

          -  Supine blood pressure ≤170/110 mmHg

          -  Documented renal impairment indicated by reduced creatinine clearance within 12 months
             of screening or longer

          -  Stable renal function as evidenced by ≤30% difference in two measurements of
             creatinine clearance on two separate occasions separated by at least 28 days with one
             measurement being the value at screening.

        Exclusion Criteria:

          -  History of renal trasplant

          -  Acute renal failure

          -  Subjects undergoing any method of dialysis or hemofiltration

          -  Evidence or history of clinically significant uncontrolled hematological, endocrine,
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or
             allergic disease (including drug allergies, but excluding untreated, asymptomatic,
             seasonal allergies at time of dosing)

          -  Disorders or surgery of the gastrointestinal tract which may interfere with drug
             absorption or may otherwise influence the pharmacokinetics of the investigational
             medicinal product (e.g., inflammatory bowel disease, resections of the small or large
             intestine, etc.)

          -  History of febrile illness within 5 days prior to dosing

          -  Evidence of clinically significant liver disease or liver damage (e.g., hepatitis B or
             C, autoimmune hepatitis, primary biliary cirrhosis, non-alcoholic fatty liver disease,
             elevated aspartate aminotransferase (AST) or alanine aminotransferase (ALT) that is
             considered clinically significant by the Investigator, etc.)

          -  Known infection with human immunodeficiency virus (HIV) upon serological testing

          -  History or presence of clinically concerning cardiac arrhythmias, or prolongation of
             Screening (pre-treatment) QT or QTc interval of >480 milliseconds (msec) for subjects
             with severe renal impairment or >450 msec for matched healthy volunteers

          -  Subjects with active or history of malignancies other than curatively treated skin
             cancer (basal cell or squamous cell carcinomas)